Why the study?
Does ME2303 improve therapeutic effects against human tumor xenografts in nude mice compared to adriamycin?
Does ME2303 improve therapeutic effects against human tumor xenografts in nude mice compared to adriamycin?
ME2303 demonstrates superior antitumor activity compared to adriamycin in human tumor xenograft models, supporting its potential for future clinical trials.
Does not support clinical use; leaves open whether ME2303 advances beyond xenograft models.
A fluorine-containing anthracycline, ME2303, given intravenously once a week for 4 weeks at the maximum tolerated doses showed better therapeutic effects against 2 gastric, 3 lung and 2 human breast tumor xenografts than did adriamycin (ADM) at the maximum tolerated dose. Among the tumors, ME2303 showed a better effect against St-40, a well-differentiated human gastric adenocarcinoma, against which ADM showed only a marginal effect. Likewise, ME2303 was more effective against Lu-24 human small cell carcinoma and MX-1 human medullary tubular adenocarcinoma than ADM. Notably, the Lu-24 tumor, developed in nude mice, disappeared after the treatment in 3 out of 6 mice. ME2303 would be an interesting compound for phase I and II clinical studies in the future.
No takes yet. Share an insight, caveat, or question.
Tsuruo et al. (1989) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: